Novartis Opens Door to Broad Dealmaking in RNAi

Novartis has seemingly changed the RNAi therapeutics game with its potential blockbuster deal with Alnylam, suggesting that getting to the bottom of RNAi's therapeutic possibilities requires significant assets and staying power.